Antitumor agent-214

Antitumor agent-214 (Compound 3f) exhibits cytotoxic activity against HCT-116 cells (IC₅₀ = 3.56 μM), MCF-7 cells (IC₅₀ = 4.08 μM), A549 cells (IC₅₀ = 12.70 μM), HeLa cells (IC₅₀ = 8.37 μM), HT-29 cells (IC₅₀ = 6.18 μM) and MD-MBA-231 cells (IC₅₀ = 10.62 μM), with lower cytotoxicity against non-cancerous cells MCF-10AMCF-10A (IC₅₀ = 9.81 μM) ^[1].
Antitumor agent-214 (1.78-7.12 μM; 24 h) causes a dose-dependent accumulation of HCT-116 cells in the sub-G1 phase, indicating induction of apoptosis^[1].
Antitumor agent-214 (3.56 μM, 7.12 μM; 24 h) induces apoptosis in HCT-116 cells as confirmed by Annexin V-FITC/PI dual staining (HY-K1073), with the apoptosis rate equivalent to that induced by Staurosporine (HY-15141), and shows weaker apoptotic effect on MCF-10A cells^[1].
Antitumor agent-214 (3.56 μM, 7.12 μM; 24 h) induces apoptosis in HCT-116 cells as demonstrated by AO-EB double staining, with the proportion of orange fluorescent apoptotic cells increasing dose-dependently^[1].
Antitumor agent-214 (3.56 μM, 7.12 μM; 24 h) increases mitochondrial superoxide production in HCT-116 cells as detected by MitoSOX Red (HY-D1055) staining^[1].
Antitumor agent-214 (7.12 μM; 24 h) induces depolarization of mitochondrial transmembrane potential in HCT-116 cells as shown by JC-1 (HY-15534) staining^[1].
Antitumor agent-214 (7.12 μM; 4-12 h) promotes the cleavage of PARP1, caspase 3, caspase 7 and caspase 9 in HCT-116 cells as analyzed by WB, with significant accumulation of cleaved proteins at 12 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.